QualityStocks would like to highlight Advaxis (
OTCBB:ADXS), a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
In the company’s news,
Advaxis announced it has received Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development for lead drug candidate ADXS-HPV to treat head and neck cancer associated with human papillomavirus (HPV).
Granted to drug therapies intended to treat diseases or conditions affecting fewer than 200,000 people in the U.S., Orphan Drug Designation entitles the sponsor to clinical protocol assistance with the FDA as well as federal grants, tax credits and, potentially, a seven-year market exclusivity period.
HPV-associated head and neck cancer represents an unmet medical need in the U.S., and patients with these cancers have limited treatment options. Advaxis hopes to improve survival rates for these patients by developing ADXS-HPV for this indication. The company intends to initiate an additional Phase 1/2 study in early-stage head and neck cancer for ADXS-HPV with a nationally recognized center of excellence. The company will continue the ongoing Phase 1 study that is being sponsored by the University of Liverpool and Aintree University Hospitals NHS Foundation Trust, which is evaluating the safety and efficacy of ADXS-HPV when combined with standard chemotherapy and radiation treatment in patients with head and neck cancer.
A clinical-stage biotechnology company, Advaxis is engaged in the development of next-generation immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bioengineered to secrete an antigen/adjuvant fusion protein(s) designed to redirect the powerful human immune response from the bacterium to the cancer itself.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit
www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
